Literature DB >> 22412090

Do platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents?: the role of platelet reactivity and genotype testing in the prevention of atherothrombotic cardiovascular events remains unproven.

Vamsi Krishna1, George A Diamond, Sanjay Kaul.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22412090     DOI: 10.1161/CIRCULATIONAHA.111.075242

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


× No keyword cloud information.
  17 in total

Review 1.  Novel anti-platelet agents in acute coronary syndrome: mechanisms of action and opportunities to tailor therapy.

Authors:  Neha Quatromoni; Sony Tuteja; Daniel M Kolanksy; William H Matthai; Jay Giri
Journal:  Curr Atheroscler Rep       Date:  2015-05       Impact factor: 5.113

Review 2.  Expert consensus document: World Heart Federation expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI.

Authors:  Glenn N Levine; Young-Hoon Jeong; Shinya Goto; Jeffrey L Anderson; Yong Huo; Jessica L Mega; Kathryn Taubert; Sidney C Smith
Journal:  Nat Rev Cardiol       Date:  2014-08-26       Impact factor: 32.419

3.  Clopidogrel Pharmacogenetics.

Authors:  Naveen L Pereira; Charanjit S Rihal; Derek Y F So; Yves Rosenberg; Ryan J Lennon; Verghese Mathew; Shaun G Goodman; Richard M Weinshilboum; Liewei Wang; Linnea M Baudhuin; Amir Lerman; Ahmed Hasan; Erin Iturriaga; Yi-Ping Fu; Nancy Geller; Kent Bailey; Michael E Farkouh
Journal:  Circ Cardiovasc Interv       Date:  2019-04       Impact factor: 6.546

4.  [Personalized therapy in cardiology. Biomarkers, pharmacogenetics and therapy of monogenic diseases].

Authors:  T Eschenhagen; S Blankenberg
Journal:  Internist (Berl)       Date:  2013-02       Impact factor: 0.743

Review 5.  Antiplatelet strategies for secondary prevention of stroke and TIA.

Authors:  Koto Ishida; Steven R Messé
Journal:  Curr Atheroscler Rep       Date:  2014-11       Impact factor: 5.113

6.  CYP2C19 genotypes and their impact on clopidogrel responsiveness in percutaneous coronary intervention.

Authors:  Melissa Mejin; Wen Ni Tiong; Lana Yin Hui Lai; Lee Len Tiong; Adam Mohamad Bujang; Siaw San Hwang; Tiong Kiam Ong; Alan Yean Yip Fong
Journal:  Int J Clin Pharm       Date:  2013-05-10

7.  Clinical determinants of clopidogrel responsiveness in a heterogeneous cohort of Puerto Rican Hispanics.

Authors:  Dagmar F Hernandez-Suarez; Stuart A Scott; Matthew I Tomey; Kyle Melin; Angel Lopez-Candales; Charlotte E Buckley; Jorge Duconge
Journal:  Ther Adv Cardiovasc Dis       Date:  2017-07-04

Review 8.  Significance of antiplatelet therapy in emergency myocardial infarction treatment.

Authors:  Anna Komosa; Maciej Lesiak; Andrzej Siniawski; Tatiana Mularek-Kubzdela; Stefan Grajek
Journal:  Postepy Kardiol Interwencyjnej       Date:  2014-03-23       Impact factor: 1.426

9.  Comparing of light transmittance aggregometry and modified thrombelastograph in predicting clinical outcomes in Chinese patients undergoing coronary stenting with clopidogrel.

Authors:  Xiao-Fang Tang; Ya-Ling Han; Jia-Hui Zhang; Jing Wang; Yin Zhang; Bo Xu; Zhan Gao; Shu-Bin Qiao; Jue Chen; Yuan Wu; Ji-Lin Chen; Run-Lin Gao; Yue-Jin Yang; Jin-Qing Yuan
Journal:  Chin Med J (Engl)       Date:  2015-03-20       Impact factor: 2.628

10.  Pharmacogenetic information in Swiss drug labels - a systematic analysis.

Authors:  C Jeiziner; K Suter; U Wernli; J M Barbarino; L Gong; M Whirl-Carrillo; T E Klein; T D Szucs; K E Hersberger; H E Meyer Zu Schwabedissen
Journal:  Pharmacogenomics J       Date:  2020-10-17       Impact factor: 3.550

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.